Golden Biotechnology Corporation (TPEX:4132)

Market Cap	3.73B
Revenue (ttm)	44.58M
Net Income (ttm)	-314.93M
Shares Out	162.23M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,678,563
Average Volume	812,175
Open	19.85
Previous Close	19.85
Day's Range	19.10 - 23.65
52-Week Range	9.98 - 23.65
Beta	0.67
RSI	89.83
Earnings Date	Nov 12, 2025

About Golden Biotechnology

Golden Biotechnology Corporation operates as a drug discovery and healthy food supplement manufacturing company in Taiwan, the United States, Japan, China, Korea, and Singapore. Its products include Liverty that is used for liver health support and fatigue; Rasle, an auto-immune adjuvant therapy; ZSAINO, a nourishment product for recovery from illness and for health improvement; and UMOOZE, a herbal formula for optimal health in males. The company also provides Antroquinonol, an anticancer molecule for the treatment of pancreatic cancer, acute ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 122
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4132

Financial Performance

In 2024, Golden Biotechnology's revenue was 40.92 million, a decrease of -35.49% compared to the previous year's 63.43 million. Losses were -360.70 million, -0.26% less than in 2023.